SCHEMBL6359180

SCHEMBL6359180

Cc1cc(C)cc(NC(=O)Cc2ccc(OC3(C(=O)CC[C@H](C)[C@H](N)C(=O)O)CCCC3)cc2)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.35
SLC1A2 P43004 1/20 0.35
SLC1A1 P43005 1/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.35
NLRP3 Q96P20 4/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CTSK P43235 1/20 0.33
RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6357002 0.91 ALDH1A1 (0.36) SLC1A3SLC1A2SLC1A1ALDH1A1MEN1
SCHEMBL6356524 0.91 ALDH1A1 (0.36) SLC1A3SLC1A2SLC1A1ALDH1A1MEN1
SCHEMBL6362121 0.86 ALDH1A1 (0.37) SLC1A3SLC1A2SLC1A1ALDH1A1MEN1
SCHEMBL6359212 0.85 LTA4H (0.39) SLC1A3SLC1A2SLC1A1ALDH1A1MEN1
SCHEMBL6362874 0.85 LTA4H (0.39) SLC1A3SLC1A2SLC1A1ALDH1A1MEN1
SCHEMBL6355468 0.82 LTA4H (0.36) SLC1A3SLC1A2SLC1A1ALDH1A1MEN1
SCHEMBL6353471 0.82 LTA4H (0.36) SLC1A3SLC1A2SLC1A1ALDH1A1MEN1
SCHEMBL6360210 0.81 ALDH1A1 (0.35) ALDH1A1MEN1KMT2APOLBL3MBTL1
SCHEMBL6358817 0.81 ALDH1A1 (0.35) ALDH1A1MEN1KMT2APOLBL3MBTL1
SCHEMBL6358103 0.81 ALDH1A1 (0.45) ALDH1A1MEN1KMT2APOLBNLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154062-A1 Substituted chiral allosteric hemoglobin modifiers ALLOS THERAPEUTICS, INC. 2005-07-14 US disclosed
US-6894185-B2 Substituted chiral allosteric hemoglobin modifiers Allós Therapeutics, Inc. (US) 2005-05-17 US disclosed
US-6486342-B1 Substituted chiral allosteric hemoglobin modifiers VIRGINIA COMMONWEALTH UNIVERSITY 2002-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154062-A1 Substituted chiral allosteric hemoglobin modifiers HBZ, HBB, HBG2 SLC1A3 4294/4885SLC1A2 4509/4885SLC1A1 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.